0 stringlengths 12 494 | embeddings listlengths 384 384 |
|---|---|
Visits to specialistsVisits to specialists\nChanges in medical/family history since last visitChanges in medical/family history since last visit\nAssess familiarity with carbohydrate counting (e.g., type 1 diabetes,Assess familiarity with carbohydrate counting (e.g., type 1 diabetes, | [
0.023902427405118942,
0.033622726798057556,
-0.010111473500728607,
0.04935447499155998,
-0.08221746236085892,
0.04742726311087608,
0.07154406607151031,
0.059794832020998,
-0.04174983128905296,
-0.06672121584415436,
-0.06664498150348663,
-0.020268291234970093,
-0.12092854827642441,
0.040044... |
type 2 diabetes treated with MDI)type 2 diabetes treated with MDI)Eating patterns and weight historyEating patterns and weight history\nTobacco, alcohol, and substance useTobacco, alcohol, and substance use\nCurrent medication planCurrent medication plan\nComplementary and alternative medicine useComplementary and alte... | [
0.024282727390527725,
0.06902958452701569,
-0.016466893255710602,
0.019740499556064606,
-0.04842056334018707,
0.062051836401224136,
0.01506028976291418,
0.038881588727235794,
-0.08854358643293381,
-0.032860491424798965,
-0.026753857731819153,
-0.011739829555153847,
-0.0916106253862381,
-0.... |
Vaccination history and needsVaccination history and needs\nGlucose monitoring (meter/CGM): results and data useGlucose monitoring (meter/CGM): results and data use\nIdentify existing social supportsIdentify existing social supports | [
-0.03355265036225319,
0.09280209243297577,
-0.05112587660551071,
0.010250000283122063,
0.004897438921034336,
0.05594540759921074,
0.02623969316482544,
0.03651371970772743,
-0.09659098833799362,
0.014843440614640713,
0.07142060995101929,
-0.04614383727312088,
0.019547484815120697,
0.0780371... |
Identify existing social supportsIdentify existing social supports\nIdentify social determinants of health (e.g., food security, housingIdentify social determinants of health (e.g., food security, housing\nstability & homelessness, transportation access, financial security,stability & homelessness, transportation acces... | [
-0.03048892319202423,
0.0025296290405094624,
-0.020275723189115524,
0.04569254815578461,
0.04955042898654938,
0.11354319006204605,
0.009165826253592968,
-0.07283759117126465,
-0.08464790880680084,
-0.07945985347032547,
0.0814816951751709,
-0.02060282975435257,
0.005808076821267605,
-0.0390... |
community safety)community safety)\nAssess daily routine and environment, including school/work schedulesAssess daily routine and environment, including school/work schedules | [
0.010028846561908722,
0.055676307529211044,
-0.009290860034525394,
0.03672689199447632,
0.07484893500804901,
0.04805593565106392,
0.05270318314433098,
-0.030046429485082626,
-0.09117017686367035,
0.017526086419820786,
0.10481835901737213,
-0.033224768936634064,
-0.03718281164765358,
0.0532... |
and ability to engage in diabetes self-managementand ability to engage in diabetes self-managementIdentify surrogate decision maker, advanced care planIdentify surrogate decision maker, advanced care planReview insulin pump settings and use, connected pen and glucose dataReview insulin pump settings and use, connected ... | [
0.005382645409554243,
0.0041453661397099495,
-0.053119029849767685,
0.05474231764674187,
-0.10111735761165619,
-0.029509106650948524,
0.09660288691520691,
0.05434861779212952,
-0.08047273010015488,
0.017228947952389717,
-0.06472746282815933,
0.020357893779873848,
-0.07970008999109268,
0.00... |
insulin pump settings and use, connected pen and glucose dataAssess use of health apps, online education, patient portals, etc.Assess use of health apps, online education, patient portals, etc.Medication intolerance or side effectsMedication intolerance or side effectsMedication-taking behavior, including rationing of ... | [
0.022771168500185013,
-0.007159681525081396,
-0.096592016518116,
0.0002837726497091353,
-0.010883617214858532,
0.005163785070180893,
0.07615052908658981,
0.10392965376377106,
-0.056907497346401215,
-0.033195652067661285,
-0.05482640489935875,
0.027326660230755806,
-0.04391706734895706,
0.0... |
effectsMedication-taking behavior, including rationing of medications and/orMedication-taking behavior, including rationing of medications and/or | [
0.06254506856203079,
-0.03484966233372688,
0.010916545987129211,
0.01118974108248949,
-0.005524780135601759,
0.07525372505187988,
-0.0005148507189005613,
0.09655850380659103,
-0.020857516676187515,
-0.036930959671735764,
0.029692884534597397,
0.02006293646991253,
0.0319548137485981,
0.0960... |
medical equipmentmedical equipmentPhysical activity and sleep behaviors; screen for obstructive sleep apneaPhysical activity and sleep behaviors; screen for obstructive sleep apneaDisability assessment and use of assistive devices (e.g., physical,Disability assessment and use of assistive devices (e.g., physical, | [
0.011392954736948013,
-0.0008190877852030098,
-0.0019255634397268295,
-0.02976643666625023,
-0.008725891821086407,
0.0709996372461319,
0.03180477023124695,
0.008906383067369461,
-0.0320691354572773,
-0.01892186887562275,
-0.0032086698338389397,
-0.03201780840754509,
0.046921711415052414,
0... |
cognitive, vision and auditory, history of fractures, podiatry)cognitive, vision and auditory, history of fractures, podiatry)\nContinued on p. S5diabetesjournals.org/care Comprehensive Medical Evaluation and Assessment of Comorbidities S55\n©AmericanDiabetesAssociation | [
0.06227964535355568,
-0.03405546769499779,
0.020793367177248,
0.008890965022146702,
-0.013403712771832943,
0.03993094712495804,
0.002561568981036544,
0.025053400546312332,
-0.08864781260490417,
0.0668540671467781,
-0.01821717619895935,
0.09444470703601837,
-0.07297036796808243,
0.018487758... |
to become severely ill with coronavirus\ndisease 2019 (COVID-19) (see DIABETES\nAND COVID -19section below). COVID-19\nvaccinations and boosters are recom-\nmended for everyone ages 6 months\nand older in the U.S. for the prevention\nof COVID-19 (17).Hepatitis B\nCompared with the general population,\npeople with type ... | [
0.020997649058699608,
0.07392667979001999,
-0.035012584179639816,
0.012930430471897125,
0.004453160334378481,
0.07760930806398392,
0.03649274632334709,
0.06322084367275238,
-0.08941392600536346,
0.013397312723100185,
0.0223715640604496,
0.03522806614637375,
-0.03309983015060425,
0.03382414... |
people with type 1 or type 2 diabetes\nhave higher rates of hepatitis. Because ofthe higher likelihood of transmission, hepa-titis B vaccine is recommended for adults\nwith diabetes aged <60 years. For adults\naged$60 years, hepatitis B vaccine maybe administered at the discretion of the\ntreating clinician based on th... | [
0.06693856418132782,
0.053614526987075806,
-0.06422865390777588,
-0.04126036912202835,
-0.08104195445775986,
0.10738832503557205,
0.036818549036979675,
0.07175920903682709,
-0.0733409970998764,
0.022185593843460083,
0.003779195249080658,
0.0018583346391096711,
-0.0038567613810300827,
0.016... |
treating clinician based on the person’ s\nlikelihood of acquiring hepatitis B infection\n(18).\nInfluenza\nInfluenza is a common, preventable infec-\ntious disease associated with high mortalityTable 4.1 (cont.) - Components of the comprehensive diabetes\nmedical evaluation at initial, follow-up, and annual visitsINITI... | [
-0.029901469126343727,
0.022163676097989082,
-0.11246544122695923,
-0.027389606460928917,
-0.10649736225605011,
0.06632114946842194,
0.01553315669298172,
0.15030743181705475,
-0.06065931171178818,
-0.039202045649290085,
-0.01738283596932888,
0.033610157668590546,
-0.012789877131581306,
0.0... |
VISITEVERY\nFOLLOW-\nUP VISIT\nComprehensive foot examination\nScreen for depression, anxiety, diabetes distress, fear of hypoglycemia, and disordered eating\nConsider assessment for cognitive performance*\nConsider assessment for functional performance*Visual inspection (e.g., skin integrity, callous formation, footde... | [
-0.022493431344628334,
-0.0018292693421244621,
-0.0014465405838564038,
0.011707748286426067,
-0.022677240893244743,
-0.03798253834247589,
0.05174880102276802,
0.002490874147042632,
-0.04277060553431511,
-0.03245904669165611,
0.038705285638570786,
0.0036256923340260983,
-0.03188188374042511,
... |
Determination of temperature, vibration or pinprick sensation,\nand 10-g monofilament examHeight, weight, and BMI; growth/pubertal development in children andadolescents\nBlood pressure determination\nOrthostatic blood pressure measures (when indicated)\nFundoscopic examination (refer to eye specialist)\nThyroid palpati... | [
0.018055986613035202,
-0.07104207575321198,
0.01475005503743887,
-0.012308726087212563,
-0.097537562251091,
-0.029434697702527046,
0.09847258031368256,
0.05538784712553024,
-0.06398085504770279,
0.05093148723244667,
0.043763864785432816,
-0.07999841868877411,
-0.0654226616024971,
0.0378035... |
Fundoscopic examination (refer to eye specialist)\nThyroid palpation\nSkin examination (e.g., acanthosis nigricans, insulin injection or\ninsertion sites, lipodystrophy)\nA1C, if the results are not available within the past 3 months\nIf not performed/available within the past year\nLiver function tests#\nSpot urinary ... | [
0.06559208780527115,
-0.08586800843477249,
-0.03015231341123581,
0.006587883923202753,
-0.013415500521659851,
-0.08680880069732666,
0.012628667987883091,
0.07423979789018631,
-0.03275953605771065,
0.020528962835669518,
-0.0111692501232028,
-0.018198365345597267,
-0.06525918841362,
0.082958... |
Liver function tests#\nSpot urinary albumin-to-creatinine ratio\nSerum creatinine and estimated glomerular filtration rate+\nThyroid-stimulating hormone in people with type 1 diabetes#\nVitamin B12 if on metformin\nSerum potassium levels in people with diabetes on ACE inhibitors, ARBs, | [
-0.010450479574501514,
-0.05096430703997612,
-0.04418709874153137,
0.011146921664476395,
-0.01996675506234169,
0.005583529826253653,
0.008195357397198677,
0.10311407595872879,
-0.049537524580955505,
-0.04502010717988014,
-0.03785756975412369,
-0.030974294990301132,
-0.0479399710893631,
0.0... |
or diuretics+Lipid profile, including total, LDL, and HDL cholesterol and\ntriglycerides#\nLABORATORY\nEVALUATIONPHYSICAL\nEXAMINATION | [
-0.038968995213508606,
-0.08583647012710571,
-0.028464071452617645,
0.012096423655748367,
-0.039170872420072556,
-0.05163893103599548,
-0.046127304434776306,
0.09450968354940414,
-0.010217800736427307,
-0.05369027331471443,
0.023929817602038383,
-0.007185711525380611,
-0.07852677255868912,
... |
triglycerides#\nLABORATORY\nEVALUATIONPHYSICAL\nEXAMINATION\nABI, ankle-brachial pressure index; ARBs, angiotensin receptor blockers; CGM, continuous glucose monitors;MDI, multiple daily injections; NAFLD, nonalcoholic fatty liver disease; OSA, obstructive sleep apnea; PAD, peripheral arterial disease.\n*At 65 years of... | [
-0.030953943729400635,
-0.03980540856719017,
-0.07759270817041397,
-0.014566991478204727,
-0.06351121515035629,
0.010814006440341473,
0.033625584095716476,
0.04087153077125549,
-0.021222900599241257,
-0.03368893638253212,
0.013215958140790462,
-0.04503617435693741,
-0.06067724898457527,
-0... |
*At 65 years of age or older.\n+May be needed more frequently in people with diabetes with known chronic kidney disease or with changes in medications that af fect kidney \nfunction and serum potassium (see Table 11.1). | [
-0.0042556109838187695,
0.021452127024531364,
-0.012257203459739685,
0.030930599197745323,
-0.1075117215514183,
0.0037394114769995213,
0.012826796621084213,
0.03977082669734955,
-0.01901915669441223,
-0.044602230191230774,
-0.0074543128721416,
0.040485598146915436,
-0.03155231848359108,
0.... |
function and serum potassium (see Table 11.1).\n#May also need to be checked after initiation or dose changes of medications that affect these laboratory values (i.e., diabetes medications, \nblood pressure medications, cholesterol medications, or thyroid medications). | [
-0.009783467277884483,
-0.06951575726270676,
-0.037718046456575394,
-0.00811807531863451,
-0.08830656111240387,
0.00311467656865716,
0.055123377591371536,
0.065642349421978,
0.033200234174728394,
-0.051969245076179504,
0.03773432597517967,
-0.008652872405946255,
-0.024780824780464172,
0.02... |
^In people without dyslipidemia and not on cholesterol-lowering therapy, testing may be less frequent.\n**Should be performed at every visit in people with diabetes with sensory loss, previous foot ulcers, or amputations.ANNUAL\nVISIT\nComplete blood count (CBC) with plateletsConsider assessment for bone pain | [
-0.0540819987654686,
0.01661033183336258,
-0.03576209023594856,
0.021760938689112663,
-0.053354788571596146,
-0.048571038991212845,
-0.06175427511334419,
0.11491967737674713,
-0.0137861929833889,
-0.06789083778858185,
0.03405573591589928,
0.031682081520557404,
-0.06533563882112503,
0.01308... |
Calcium, vitamin D, and phosphorous for appropriate people with diabetesScreen for PAD (pedal pulses—refer for ABI if diminished)S56 Comprehensive Medical Evaluation and Assessment of Comorbidities Diabetes Care Volume 47, Supplement 1, January 2024\n©AmericanDiabetesAssociation | [
-0.038867391645908356,
-0.035175397992134094,
-0.03009697236120701,
0.005778140854090452,
-0.06611499935388565,
-0.030968045815825462,
0.091607965528965,
0.054370809346437454,
0.013510317541658878,
0.023541981354355812,
0.01860891468822956,
0.049468617886304855,
-0.033359594643116,
-0.0293... |
and morbidity in vulnerable populations,\nincluding youth, older adults, and peoplewith chronic diseases. In fluenza vaccination\nin people with diabetes has been found to\nsignificantly reduce infl uenza and diabetes-\nrelated hospital admissions (19). In people\nwith diabetes and cardiovascular disease,influenza vaccine ... | [
-0.011394710280001163,
0.09879476577043533,
-0.08408617228269577,
0.041726358234882355,
-0.05307725816965103,
0.04512044042348862,
0.08183687180280685,
0.09277450293302536,
-0.09310344606637955,
-0.01229165680706501,
0.06391353160142899,
0.08305168151855469,
0.01614738628268242,
0.07721525... |
lower risk of all-cause mortality, cardiovas-\ncular mortality, and cardiovascular events\n(20). Given the bene fits of the annual in-\nfluenza vaccination, it is recommended\nfor all individuals $6 months of age who\ndo not have a contraindication. The live\nattenuated in fluenza vaccine, which is de-\nlivered by nasal s... | [
0.04623015597462654,
0.09897023439407349,
0.0005280307377688587,
-0.025733264163136482,
-0.01508646085858345,
0.06551333516836166,
0.033863384276628494,
0.12527866661548615,
-0.08070419728755951,
0.04662285000085831,
0.08095265179872513,
0.028732214123010635,
0.05681208521127701,
0.0498764... |
livered by nasal spray, is an option for\npeople who are 2 –49 years of age and\nwho are not pregnant, but people withchronic conditions such as diabetes are\ncautioned against taking the liveattenuated in fluenza vaccine and are in-\nstead recommended to receive the inac-tive or recombinant in fluenza vaccination. | [
-0.0284061711281538,
0.016208365559577942,
-0.058997511863708496,
-0.014823655597865582,
-0.014815939590334892,
0.03717369958758354,
0.057245541363954544,
0.11199025064706802,
-0.10909699648618698,
0.061063628643751144,
0.05592602118849754,
-0.006940273568034172,
-0.04444720596075058,
0.05... |
For individuals $65 years of age, there\nmay be additional bene fit from the high-\ndose quadrivalent inactivated in fluenza\nvaccine (21).\nPneumococcal Pneumonia\nLike in fluenza, pneumococcal pneumonia\nis a common, preventable disease. Peoplewith diabetes are at increased risk for\npneumococcal infection and have been... | [
0.034488700330257416,
0.01836649887263775,
-0.05210353434085846,
0.06117084249854088,
-0.04508298262953758,
0.08526160567998886,
0.03165864571928978,
0.10104411840438843,
-0.02558276429772377,
0.01954709179699421,
0.04464001953601837,
0.02885487861931324,
0.0312773659825325,
0.061966083943... |
pneumococcal infection and have been re-\nported to have a high risk of hospitaliza-tion and death, with a mortality rate ashigh as 50% (22). There are two types ofvaccines available in the U.S., pneumococ-cal conjugate vaccines (PCV13, PCV15, andPCV20) and pneumococcal polysaccharidevaccine (PPSV23), with distinct sch... | [
-0.005388977006077766,
-0.05823139473795891,
-0.08435161411762238,
-0.060846079140901566,
-0.020764583721756935,
0.07524193823337555,
-0.04009430855512619,
0.0827944278717041,
0.04510878026485443,
0.06394118815660477,
0.035034067928791046,
0.04977089539170265,
0.05204010754823685,
0.097376... |
for children and adults.\nIt is recommended that all children re-\nceive a four-dose series of PCV13 orP C V 1 5b y1 5m o n t h so fa g e .F o rc h i l d r e n\nwith diabetes who have incomplete se-\nries by ages 2 –5 years, the CDC recom-\nmends a catch-up schedule to ensurethat these children have four doses. Chil- | [
-0.01672971621155739,
0.010232822969555855,
-0.01315397024154663,
-0.018729781731963158,
-0.04465058073401451,
0.03025882877409458,
-0.004154668655246496,
0.09348306804895401,
-0.021133093163371086,
-0.0022539282217621803,
0.044908326119184494,
0.08314017206430435,
-0.09234289824962616,
0.... |
dren with diabetes between 6 and 18 years\nof age are also advised to receive one\ndose of PPSV23, preferably after receipt\nof PCV13.\nAdults aged $65 years whose vac-\ncine status is unknown or who have notreceived pneumococcal vaccine should\nreceive one dose of PCV15 or PCV20. If\nPCV15 is used, it should be follow... | [
-0.03888169676065445,
0.06535511463880539,
-0.018709653988480568,
-0.083194799721241,
-0.0237907562404871,
0.02432170882821083,
0.061350155621767044,
0.07450475543737411,
-0.048530980944633484,
0.011674195528030396,
0.04600267857313156,
0.000433922978118062,
-0.020611921325325966,
0.053573... |
PCV15 is used, it should be followed by\nPPSV23.\nAdults aged 19 –64 years with certain\nunderlying risk factors or other medicalconditions whose vaccine status is un-\nknown or who have not received pneu-\nmococcal vaccine should receive one\ndose of PCV15 or PCV20. As for adults\naged$65 years, if PCV15 is used, it\n... | [
-0.031241511926054955,
0.0692155584692955,
-0.023540591821074486,
-0.11593100428581238,
-0.005821042228490114,
0.04874953627586365,
0.006691431626677513,
0.055698975920677185,
-0.020716780796647072,
0.01120204571634531,
0.07522184401750565,
0.0033792913891375065,
-0.008564271032810211,
0.0... |
aged$65 years, if PCV15 is used, it\nshould be followed by PPSV23.\nThe recommended interval between\nPCV15 and PPSV23 is $1y e a r .I fP P S V 2 3i s\nthe only dose received, PCV15 or PCV20may be given $1 year later.\nFor adults with immunocompromising\nconditions, cochlear implant, or cerebro-spinal fluid leak, a mini... | [
-0.04556795209646225,
0.04727630317211151,
-0.0014612085651606321,
-0.11352477222681046,
-0.05430878698825836,
0.011891955509781837,
-0.005504942964762449,
0.1251397728919983,
-0.02350597456097603,
0.017781293019652367,
0.05050007253885269,
-0.01205877959728241,
-0.023557445034384727,
0.09... |
8 weeks can be considered for dosing ofPCV15 and PPSV23 when PCV15 has been\nused.\nAdults who received PCV13 should fol-\nlow the previously recommended PPSV23series (23 –26). Adults who received only\nPPSV23 may receive PCV15 or PCV20$1 year after their last dose.\nRespiratory Syncytial Virus\nRespiratory syncytial v... | [
-0.012647678144276142,
0.019473785534501076,
0.008132820017635822,
-0.06480752676725388,
0.056578293442726135,
0.01046643778681755,
-0.00249118241481483,
0.06419672816991806,
0.008069018833339214,
-0.00651880307123065,
0.09766127169132233,
0.025938117876648903,
-0.017035607248544693,
0.083... |
Respiratory syncytial virus (RSV) is a cause\nof respiratory illness in older adults. Peo-\nple with chronic conditions such as diabe-\ntes have a higher risk of severe illness. The\nFood and Drug Administration (FDA) ap-\nproved the first vaccines for prevention of\nRSV-associated lower respiratory tract dis-ease in ad... | [
-0.016436904668807983,
0.039144765585660934,
-0.0646054670214653,
0.005743866786360741,
0.015007167123258114,
0.07379357516765594,
-0.014987730421125889,
0.07630745321512222,
-0.014732505194842815,
0.06463596969842911,
0.014373227953910828,
0.08237547427415848,
0.07804682105779648,
0.04876... |
2023, ACIP voted to recommend thatadults aged $60 years may receive a sin-\ng l ed o s eo fa nR S Vv a c c i n e ,u s i n gs h a r e dclinical decision-making. The ACIP Respira-\ntory Syncytial Virus Vaccines Adult Work\nGroup continues to monitor the effi cacyTable 4.2 —Assessment and treatment plan\nAssessing risk of ... | [
-0.059085436165332794,
0.03441765159368515,
-0.06178082525730133,
0.012484191916882992,
-0.03337906673550606,
0.09078723192214966,
0.030832428485155106,
0.07698776572942734,
-0.028997980058193207,
0.049280211329460144,
0.03592162951827049,
0.07624932378530502,
-0.037677474319934845,
-0.000... |
Assessing risk of diabetes complications\n/C15ASCVD and heart failure history\n/C15ASCVD risk factors and 10-year ASCVD risk assessment\n/C15Staging of chronic kidney disease (see Table 11.1 )\n/C15Hypoglycemia risk (see Section 6, “Glycemic Goals and Hypoglycemia ”)\n/C15Assessment for retinopathy\n/C15Assessment for ... | [
-0.05371668562293053,
0.002938278717920184,
-0.023764081299304962,
0.03437110036611557,
0.007297912146896124,
0.041460081934928894,
-0.017321735620498657,
0.1283826380968094,
-0.10544770210981369,
-0.023411735892295837,
-0.013874506577849388,
-0.050271760672330856,
-0.07849317044019699,
-0... |
/C15Assessment for retinopathy\n/C15Assessment for neuropathy\n/C15Assessment for NAFLD/NASH\nGoal setting\n/C15Set A1C/blood glucose/time in range\n/C15If hypertension is present, establish blood pressure goal\n/C15Weight management and physical activity goals\n/C15Diabetes self-management goals\nTherapeutic treatment... | [
-0.06069875881075859,
0.03718448430299759,
-0.004963839892297983,
-0.0009486477938480675,
-0.0417768731713295,
0.02564176172018051,
-0.01827569119632244,
0.07197672873735428,
-0.10096163302659988,
-0.005981531459838152,
-0.010516551323235035,
-0.08653821051120758,
-0.09494258463382721,
0.0... |
Therapeutic treatment plans\n/C15Lifestyle management\n/C15Pharmacologic therapy: glucose lowering\n/C15Pharmacologic therapy: cardiovascular and kidney disease risk factors\n/C15Weight management with pharmacotherapy or metabolic surgery, as appropriate\n/C15Use of glucose monitoring and insulin delivery devices | [
-0.06088375300168991,
0.0850558876991272,
0.003467405214905739,
0.0018192159477621317,
-0.04339103773236275,
-0.017904894426465034,
-0.02312093786895275,
0.10449211299419403,
-0.05352098122239113,
-0.04814900457859039,
-0.06848576664924622,
0.010895493440330029,
-0.09525847434997559,
0.000... |
/C15Use of glucose monitoring and insulin delivery devices\n/C15Referral to diabetes education, behavioral health, and medical specialists\nAssessment and treatment planning are essential components of initial and all follow-up vis- | [
-0.050543397665023804,
0.06279410421848297,
-0.04716900363564491,
0.040366578847169876,
0.0047576166689395905,
0.01635861024260521,
0.06122780218720436,
0.0951923206448555,
-0.01984931342303753,
-0.009727930650115013,
-0.0413922518491745,
0.024054408073425293,
-0.08300237357616425,
0.03282... |
its. ASCVD, atherosclerotic cardiovascular disease; NAFLD, nonalcoholic fatty liver disease;NASH, nonalcoholic steatohepatitis.\nTable 4.3 —Referrals for initial care management\n/C15Eye care professional for annual dilated eye exam\n/C15Family planning for individuals of childbearing potential | [
0.007165899965912104,
-0.049876924604177475,
-0.028577057644724846,
0.00018664893286768347,
-0.027784980833530426,
0.035100970417261124,
-0.0033489943016320467,
0.06142078712582588,
-0.025443751364946365,
0.01338066253811121,
0.044415365904569626,
-0.05659908428788185,
-0.08644282817840576,
... |
/C15Family planning for individuals of childbearing potential\n/C15Registered dietitian nutritionist for medical nutrition therapy\n/C15Diabetes self-management education and support\n/C15Dentist for comprehensive dental and periodontal examination\n/C15Behavioral health professional, if indicated\n/C15Audiology, if in... | [
-0.09798465669155121,
0.03731466084718704,
-0.008166080340743065,
0.02409897744655609,
-0.020952701568603516,
0.038321640342473984,
-0.030875055119395256,
0.07033519446849823,
-0.06719320267438889,
-0.03258331120014191,
-0.03966105729341507,
-0.07083004713058472,
-0.12953519821166992,
-0.0... |
/C15Audiology, if indicated\n/C15Social worker/community resources, if indicated\n/C15Rehabilitation medicine or another relevant health care professional for physical and\ncognitive disability evaluation, if indicated | [
-0.04004981368780136,
0.017079325392842293,
-0.019708480685949326,
0.00631910003721714,
-0.00012612840509973466,
0.0349489189684391,
0.012382008135318756,
0.09304249286651611,
-0.02608446776866913,
-0.07789721339941025,
-0.035140447318553925,
-0.06775684654712677,
-0.08038023859262466,
0.0... |
cognitive disability evaluation, if indicated\n/C15Other appropriate health care professionalsdiabetesjournals.org/care Comprehensive Medical Evaluation and Assessment of Comorbidities S57\n©AmericanDiabetesAssociation | [
0.02228543721139431,
0.056383099406957626,
-0.09529230743646622,
0.05018546059727669,
-0.043848562985658646,
0.10574565082788467,
0.0409209318459034,
0.06700770556926727,
-0.0739058256149292,
0.008664470165967941,
-0.02170170098543167,
0.024263640865683556,
-0.09504774212837219,
0.03375934... |
Table 4.4 —Highly recommended immunizations for adults with diabetes (Advisory Committee on Immunization Practices\nand Centers for Disease Control and Prevention)\nVaccine Recommended ages Schedule GRADE evidence type* References\nCOVID-19 Recommended for all\n6 months of age\nand olderCurrent initial vaccination | [
-0.008404824882745743,
0.016451148316264153,
-0.061025481671094894,
-0.01783825270831585,
-0.036770615726709366,
0.09847405552864075,
0.05918974429368973,
0.10328246653079987,
-0.08452706038951874,
0.04329099878668785,
-0.009985269978642464,
0.05272594094276428,
-0.005841846112161875,
0.06... |
6 months of age\nand olderCurrent initial vaccination\nand boostersCenters for Disease Control and\nPrevention, Interim ClinicalConsiderations for Use of COVID-19\nVaccines, 2023 (295)\nHepatitis B Recommended for adults with\ndiabetes aged <60 years; for\nadults aged $60 years, | [
0.027542289346456528,
0.023724457249045372,
-0.06401044130325317,
0.008261512033641338,
-0.07040876895189285,
0.08668536692857742,
0.004263199400156736,
0.08244680613279343,
-0.08287844806909561,
0.038706645369529724,
0.011661599390208721,
0.006594098638743162,
-0.010535704903304577,
0.029... |
diabetes aged <60 years; for\nadults aged $60 years,\nhepatitis B vaccine may beadministered at the discretionof the treating clinician based\non the person ’s likelihood of\nacquiring hepatitis B infectionWeng et al., Universal Hepatitis B\nVaccination in Adults Aged 19 –59\nYears: Updated Recommendations | [
0.042210668325424194,
0.08139946311712265,
-0.06984778493642807,
-0.041954126209020615,
-0.07236020267009735,
0.11486117541790009,
0.03973953425884247,
0.04561088606715202,
-0.11497113853693008,
0.001988130621612072,
-0.01986568048596382,
-0.0007800563471391797,
0.023459983989596367,
0.009... |
Vaccination in Adults Aged 19 –59\nYears: Updated Recommendations\nof the Advisory Committee onImmunization Practices —United\nStates, 2022 (18)\nInfluenza All people with diabetes advised\nnot to receive live attenuatedinfluenza vaccineAnnual Centers for Disease Control and\nPrevention, Prevention and Controlof Seasonal... | [
-0.00010705335444072261,
0.05690746754407883,
-0.07361151278018951,
0.05034976825118065,
-0.08779164403676987,
0.06099585443735123,
0.07400669902563095,
0.028550894930958748,
-0.10441020131111145,
-0.008839299902319908,
-0.001745495479553938,
0.051678337156772614,
-0.021535497158765793,
0.... |
Recommendations of the AdvisoryCommittee on Immunization\nPractices —United States, 2023– 24\nInfluenza Season (296)\nPneumonia (PPSV23\n[Pneumovax])19–64 years of age, vaccinate\nwith PneumovaxOne dose is recommended for those who\npreviously received PCV13; if PCV15\nwas used, follow with PPSV23 $1y e a r | [
-0.025300513952970505,
0.03594742342829704,
-0.028927985578775406,
-0.09714144468307495,
-0.03592247515916824,
0.049094703048467636,
0.033798638731241226,
0.11094968020915985,
-0.050798200070858,
0.03376288712024689,
0.023629870265722275,
0.05211412534117699,
-0.005379675887525082,
0.09728... |
was used, follow with PPSV23 $1y e a r\nlater; PPSV23 is not indicated afterPCV20; adults who received only\nPPSV23 may receive PCV15 or PCV20\n$1 year after their last dose2 Centers for Disease Control and\nPrevention, UpdatedRecommendations for Prevention ofInvasive Pneumococcal DiseaseAmong Adults Using the 23-Valen... | [
-0.051907703280448914,
0.046086423099040985,
-0.0394851416349411,
-0.08588448911905289,
0.009814972057938576,
0.06930757313966751,
0.02616429328918457,
0.11021738499403,
0.013086732476949692,
0.005271418485790491,
0.08842629939317703,
0.0205624271184206,
-0.0050240312702953815,
0.064991556... |
Pneumococcal Polysaccharide\nVaccine (PPSV23) (23)\n$65 years of age One dose is recommended for those\nwho previously received PCV13; ifPCV15 was used, follow with PPSV23$1 year later; PPSV23 is not\nindicated after PCV20; adults whoreceived only PPSV23 may receivePCV15 or PCV20 $1 year after their\nlast dose2 Falkenh... | [
-0.005397259723395109,
-0.0078959371894598,
-0.052426040172576904,
-0.07531265914440155,
-0.04396872967481613,
0.06367067247629166,
0.02479207143187523,
0.12816832959651947,
0.02606491558253765,
0.028162257745862007,
0.0799548402428627,
0.05051518976688385,
0.00859846081584692,
0.095745347... |
last dose2 Falkenhorst et al., Effectiveness of the\n23-Valent PneumococcalPolysaccharide Vaccine (PPV23)Against Pneumococcal Disease in\nthe Elderly: Systematic Review and\nMeta-analysis (24)\nPCV20 or PCV15 Adults 19 –64 years of age, with\nan immunocompromisingcondition (e.g., chronic renalfailure), cochlear implant... | [
0.0006950773531571031,
0.008642070926725864,
-0.06371491402387619,
-0.07838281989097595,
-0.06286869943141937,
0.04190525785088539,
-0.00263254065066576,
0.11053038388490677,
-0.0607103630900383,
0.02941659837961197,
0.027483386918902397,
0.0512971356511116,
0.07176713645458221,
0.06596571... |
cerebrospinal fluid leakOne dose of PCV15 or PCV20 is\nrecommended by the Centers for\nDisease Control and Prevention3 Kobayashi et al., Use of 15-Valent\nPneumococcal Conjugate Vaccineand 20-Valent PneumococcalConjugate Vaccine Among U.S.\nAdults: Updated Recommendations\nof the Advisory Committee on\nImmunization Prac... | [
0.010571948252618313,
-0.003045502817258239,
0.008186599239706993,
-0.06272513419389725,
-0.0007844889769330621,
0.03254872187972069,
0.05338156968355179,
0.10433453321456909,
0.03898349031805992,
0.0539943091571331,
0.0631316676735878,
-0.023428253829479218,
-0.018332919105887413,
0.08608... |
of the Advisory Committee on\nImmunization Practices —United\nStates, 2022 (25)19–64 years of age,\nimmunocompetentFor those who have never received any\npneumococcal vaccine, the CDCrecommends one dose of PCV15 orPCV20\n$65 years of age, | [
0.023332836106419563,
0.05593341216444969,
-0.030678164213895798,
-0.04949450492858887,
-0.010565423406660557,
0.06166106089949608,
-0.02003878355026245,
0.05230209603905678,
-0.06673265248537064,
0.07080495357513428,
0.07433654367923737,
0.012429274618625641,
0.015424135141074657,
0.06697... |
$65 years of age,\nimmunocompetent, haveshared decision-makingdiscussion with health careprofessionalsOne dose of PCV15 or PCV20; PCSV23\nmay be given $8 weeks after PCV15;\nPPSV23 is not indicated after PCV20\nRSV Older adults $60 years of age\nwith diabetes appear to be arisk groupAdults aged $60 years may receive a | [
-0.005792361218482256,
0.11954764276742935,
-0.01826397143304348,
-0.043935175985097885,
-0.028229152783751488,
0.06184099242091179,
0.023324767127633095,
0.059509195387363434,
-0.028162578120827675,
0.0455322228372097,
0.027415797114372253,
-0.014791934750974178,
-0.03570861741900444,
0.0... |
single dose of an RSV vaccineCenters for Disease Control and\nPrevention, CDC Recommends RSVVaccine for Older Adults (29)\nTetanus, diphtheria,\npertussis (Tdap)All adults; pregnant individuals\nshould have an extra doseBooster every 10 years 2 for effectiveness,\n3 for safetyHavers et al., Use of Tetanus Toxoid, | [
-0.004646873101592064,
-0.013413628563284874,
-0.06312651187181473,
-0.03476225584745407,
-0.0007825834327377379,
0.05851946026086807,
-0.030920306220650673,
0.1363205462694168,
-0.019053734838962555,
0.07036508619785309,
0.027946190908551216,
0.0291779525578022,
0.06864157319068909,
0.099... |
3 for safetyHavers et al., Use of Tetanus Toxoid,\nReduced Diphtheria Toxoid, andAcellular Pertussis Vaccines:\nUpdated Recommendations of the\nAdvisory Committee on\nImmunization Practices —United\nStates, 2019 (297) | [
-0.010004270821809769,
0.046429164707660675,
-0.013248284347355366,
-0.06485603749752045,
-0.030814670026302338,
0.06300532072782516,
0.024030892178416252,
0.10459943860769272,
-0.0594082735478878,
0.09480633586645126,
0.02164783887565136,
0.02058866061270237,
0.04316648468375206,
0.082296... |
Immunization Practices —United\nStates, 2019 (297)\nContinued on p. S59S58 Comprehensive Medical Evaluation and Assessment of Comorbidities Diabetes Care Volume 47, Supplement 1, January 2024\n©AmericanDiabetesAssociation | [
0.03481917083263397,
0.022371692582964897,
-0.058358997106552124,
0.045491646975278854,
-0.06894698739051819,
0.05361286923289299,
0.07917739450931549,
0.06676296889781952,
-0.07815482467412949,
-0.016900403425097466,
-0.014923465438187122,
0.0637921392917633,
-0.03299105167388916,
0.01695... |
of these vaccines among adults aged\n$60 years (27 –29).\nASSESSMENT OF COMORBIDITIES\nBesides assessing diabetes-related com-plications, clinicians and people withdiabetes need to be aware of commoncomorbidities that affect people with dia-betes and that may complicate manage-ment (30 –32). Diabetes comorbidities are | [
0.07559074461460114,
0.04736299440264702,
-0.04939338192343712,
-0.017144331708550453,
-0.06325630843639374,
0.06167149916291237,
0.10768940299749374,
0.0628112256526947,
-0.061724528670310974,
0.0022134992759674788,
-0.02006388083100319,
0.028235362842679024,
0.0038701759185642004,
0.0232... |
conditions that affect people with diabe-tes more often than age-matched peoplewithout diabetes. This section discusses\nmany of the common comorbidities ob-\nserved in people with diabetes but is notnecessarily inclusive of all the conditionsthat have been reported.\nAutoimmune Diseases\nRecommendations\n4.7People wit... | [
0.04186800494790077,
0.04864322766661644,
-0.006932511460036039,
0.03934577479958534,
-0.09508314728736877,
0.03733723610639572,
0.14044347405433655,
0.07031223177909851,
-0.0921764150261879,
-0.0251305028796196,
-0.01225951500236988,
0.02888096496462822,
-0.06490292400121689,
0.0029993804... |
Recommendations\n4.7People with type 1 diabetes should\nbe screened for autoimmune thyroiddisease soon after diagnosis and peri-odically thereafter. B\n4.8Adults with type 1 diabetes should\nbe screened for celiac disease in thepresence of gastrointestinal symptoms,\nsigns, laboratory manifestations, or clin- | [
0.008764347061514854,
-0.029946526512503624,
-0.005410504527390003,
-0.02309521660208702,
-0.047104619443416595,
0.01641872525215149,
0.07499569654464722,
0.038392502814531326,
-0.06058738753199577,
-0.04679390415549278,
0.01128422562032938,
0.002150734653696418,
-0.0954785868525505,
0.022... |
signs, laboratory manifestations, or clin-\nical suspicion suggestive of celiac dis-ease. B\nPeople with type 1 diabetes are at in-\ncreased risk for other autoimmune dis-\neases, with thyroid disease, celiac disease,\nand pernicious anemia (vitamin B12\ndeficiency) being among the most com-\nmon (33). Other associated ... | [
-0.034771934151649475,
-0.04013051465153694,
-0.0464303120970726,
0.013874122872948647,
0.0008822738309390843,
-0.0034717631060630083,
0.10603361576795578,
0.07568678259849548,
-0.03649001196026802,
-0.047181107103824615,
0.0058747571893036366,
-0.05490100011229515,
-0.032358910888433456,
... |
mon (33). Other associated conditions\ninclude autoimmune liver disease, pri-\nmary adrenal insuf ficiency (Addison dis-\nease), collagen vascular diseases, andmyasthenia gravis (34 –37). Type 1 diabe-\ntes may also occur with other autoim-\nmune diseases in the context of speci fic | [
-0.04417512193322182,
0.019295543432235718,
-0.035643335431814194,
0.027568843215703964,
-0.018887829035520554,
-0.058106061071157455,
0.010958677157759666,
0.08770842850208282,
-0.04034184664487839,
0.014445476233959198,
0.01362590305507183,
-0.05654226616024971,
-0.07070480287075043,
0.0... |
mune diseases in the context of speci fic\ngenetic disorders or polyglandular auto-immune syndromes (38). Given the highprevalence, nonspeci fics y m p t o m s ,a n di n -\nsidious onset of primary hypothyroidism,\nroutine screening for thyroid dysfunction is\nrecommended for all people with type 1diabetes. Screening for... | [
-0.03142637759447098,
-0.022224564105272293,
0.015042213723063469,
-0.022873710840940475,
-0.01708517223596573,
-0.024755917489528656,
0.05366610735654831,
0.09532575309276581,
-0.04738309234380722,
-0.011149230413138866,
0.00222263322211802,
-0.011089126579463482,
-0.009647930040955544,
-... |
should be considered in adults with dia-\nbetes with suggestive symptoms (e.g.,diarrhea, malabsorption, and abdominal\npain) or signs (e.g., osteoporosis, vitamin\ndeficiencies, and iron defi ciency anemia)\n(39,40). Measurement of vitamin B12\nlevels should be considered for people\nwith type 1 diabetes and peripheral n... | [
-0.017859380692243576,
-0.0003549990360625088,
-0.09254022687673569,
0.04370008409023285,
-0.0722568929195404,
-0.004654506221413612,
0.08443865180015564,
0.03600538894534111,
-0.0396149642765522,
-0.0547054298222065,
-0.028475727885961533,
-0.014452708885073662,
-0.05655253678560257,
0.02... |
Bone Health\nRecommendations\n4.9Fracture risk should be assessed\nin older adults with diabetes as a\npart of routine care in diabetes clin-\nical practice, according to risk fac-\ntors and comorbidities. A\n4.10 Monitor bone mineral density\nusing dual-energy X-ray absorptiome-\ntry of high-risk older adults with dia... | [
-0.026115870103240013,
0.01718306913971901,
-0.02729325369000435,
-0.0017175170360133052,
-0.058094654232263565,
-0.0010187652660533786,
0.02818583883345127,
0.07414457947015762,
-0.10098731517791748,
0.001016900292597711,
-0.02602227032184601,
0.03237086161971092,
-0.027161967009305954,
0... |
betes (aged >65 years) and younger\nindividuals with diabetes and multiplerisk factors every 2 –3 years. A\n4.11 Clinicians should consider the po-\ntential adverse impact on bone healthwhen selecting pharmacological op-tions to lower glucose levels in people\nwith diabetes. Prioritizing medications\nwith a proven safe... | [
-0.04916192591190338,
0.054183151572942734,
-0.01615963503718376,
0.0089293597266078,
-0.09621473401784897,
-0.021771125495433807,
0.026726804673671722,
0.09562902897596359,
-0.03943687677383423,
0.054653964936733246,
-0.012494792230427265,
0.11380261927843094,
-0.02682444639503956,
0.0177... |
with a proven safety pro file for bones\nis recommended, particularly for thoseat elevated risk for fractures. A\n4.12 To reduce the risk of falls and\nfractures, glycemic management goalsshould be individualized for people\nwith diabetes at a higher risk of frac-\nture. CPrioritize use of glucose-lowering\nmedications ... | [
-0.06664308160543442,
0.05140126496553421,
-0.002981879748404026,
-0.015733839944005013,
-0.044451966881752014,
-0.0009422292932868004,
0.015103903599083424,
0.10851801931858063,
-0.07861881703138351,
0.02702011726796627,
0.016669977456331253,
0.07132566720247269,
-0.07201164215803146,
0.0... |
medications that are associated with\nlow risk for hypoglycemia to avoid\nfalls. ETable 4.4 —Continued\nVaccine Recommended ages Schedule GRADE evidence type* References\nZoster $50 years of age Two-dose Shingrix, even if\npreviously vaccinated1 Dooling et al., Recommendations of\nthe Advisory Committee on | [
0.04459534212946892,
0.06811022013425827,
-0.016879945993423462,
0.03760109469294548,
-0.025123700499534607,
0.005492665804922581,
0.025210656225681305,
0.13443328440189362,
-0.07097838819026947,
-0.004427608102560043,
-0.03617377579212189,
0.02128402329981327,
0.057496897876262665,
0.0615... |
the Advisory Committee on\nImmunization Practices for Use ofHerpes Zoster Vaccines (298)\nFor a comprehensive list of vaccines, refer to the Centers for Disease Control and Prevention web site at cdc.gov/vaccines/. Advisory Commit- | [
-0.009963927790522575,
-0.012509682215750217,
-0.0684564933180809,
0.0458272360265255,
0.012355935759842396,
0.0057864123955369,
-0.004083946347236633,
0.0731031596660614,
-0.034867558628320694,
0.05005394294857979,
-0.02600237913429737,
-0.013742281123995781,
0.0035456193145364523,
0.0647... |
tee on Immunization Practices recommendations can be found at cdc.gov/vaccines/acip/recommendations. GRADE, Grading of Recommendations\nAssessment, Development, and Evaluation; PCV13, 13-valent pneumococcal conjugate vaccine; PCV15, 15-valent pneumococcal conjugate vaccine; | [
0.002198614180088043,
-0.018065670505166054,
-0.04134290665388107,
-0.044574152678251266,
-0.03998987004160881,
-0.007786159869283438,
-0.015978949144482613,
0.13407042622566223,
-0.06752476096153259,
0.03863905742764473,
0.027794623747467995,
-0.014869483187794685,
-0.025699783116579056,
... |
PCV 20, 20-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine. *Evidence type: 1, randomized con-trolled trials (RCTs) or overwhelming evidence from observational studies; 2, RCTs with important limitations or exceptionally strong evidence | [
-0.017651481553912163,
0.00549545232206583,
-0.029692988842725754,
-0.030846601352095604,
0.06129632145166397,
0.07041227072477341,
0.032720278948545456,
0.10184092819690704,
0.08328329026699066,
0.0608440600335598,
-0.012930570170283318,
0.025459108874201775,
0.06521197408437729,
0.075173... |
from observational studies; 3, observational studies or RCTs with notable limitations; 4, clinical experience and observations, observational\nstudies with important limitations, or RCTs with several major limitations.\nTable 4.5 —General and diabetes-specifi c risk factors for fracture\nGeneral risk factors\n/C15Prior ... | [
-0.01852588728070259,
-0.01598658598959446,
0.026360973715782166,
0.046495646238327026,
0.06740449368953705,
0.015443024225533009,
-0.07232064753770828,
0.16816984117031097,
-0.02680227719247341,
0.008220842108130455,
-0.05260586738586426,
-0.008894241414964199,
-0.04943867027759552,
0.026... |
General risk factors\n/C15Prior osteoporotic fracture\n/C15Age>65 years\n/C15Low BMI\n/C15Sex\n/C15Malabsorption\n/C15Recurrent falls\n/C15Glucocorticoid use\n/C15Family history\n/C15Alcohol/tobacco abuse\n/C15Rheumatoid arthritis\nDiabetes-speci fic risk factors\n/C15Lumbar spine or hip T-score #/C02.0\n/C15Frequent hy... | [
-0.006907477043569088,
0.020998137071728706,
0.011441695503890514,
0.04195393994450569,
-0.016176000237464905,
0.013043774291872978,
-0.06806814670562744,
0.14410555362701416,
-0.05219510942697525,
-0.006626105401664972,
-0.05147051811218262,
-0.038038019090890884,
-0.055198948830366135,
-... |
/C15Frequent hypoglycemic events\n/C15Diabetes duration >10 years\n/C15Diabetes medications: insulin, thiazolidinediones, sulfonylurea\n/C15A1C>8%\n/C15Peripheral and autonomic neuropathy\n/C15Retinopathy and nephropathydiabetesjournals.org/care Comprehensive Medical Evaluation and Assessment of Comorbidities S59\n©Ame... | [
-0.03167588636279106,
-0.028351066634058952,
-0.04557470232248306,
0.08428356796503067,
-0.04274417459964752,
-0.0023904629051685333,
-0.018905937671661377,
0.10210508108139038,
-0.07289368659257889,
-0.07145936787128448,
-0.00037068809615448117,
0.003766237525269389,
-0.053201254457235336,
... |
4.13 Advise people with diabetes on\ntheir intake of calcium and vitamin D\nto ensure it meets the recommended\ndaily allowance for those at risk forfracture, either through their diet orsupplemental means. B\n4.14 Antiresorptive medications and\nosteoanabolic agents should be con-sidered for people with diabetes whoha... | [
-0.03769772872328758,
0.04866962507367134,
0.031293198466300964,
-0.021024323999881744,
-0.05142265930771828,
0.01948048174381256,
0.07389464229345322,
0.08414679020643234,
-0.060710083693265915,
0.011022069491446018,
0.020116051658988,
0.012270970270037651,
-0.07060007750988007,
0.0236660... |
T-score #/C02.0 or have experienced\nfragility fractures. B\nFracture risk has traditionally relied on\nmeasurements of bone mineral density(BMD) and the World Health Organization–defined T-score of #/C02.5 SD. However, it is | [
-0.00951574370265007,
0.004814960062503815,
0.014079039916396141,
0.008440664038062096,
-0.013177566230297089,
0.041563235223293304,
0.0029308253433555365,
0.15639203786849976,
-0.04719272628426552,
0.02917676977813244,
-0.000563838635571301,
-0.05365816131234169,
0.008681005798280239,
0.0... |
now established that the consideration ofother risk factors improves the categoriza-tion of fracture risk ( Table 4.5 ). There are\nfactors beyond BMD testing that contribute\nto bone strength in people with diabetes.\nHip or vertebral fracture with low trauma\nin people aged $65 years is diagnostic\nfor osteoporosis i... | [
-0.014633654616773129,
-0.024703606963157654,
-0.01078465674072504,
0.01089191809296608,
-0.01872800849378109,
0.029798312112689018,
-0.024175724014639854,
0.10535503923892975,
-0.10586557537317276,
0.04470226541161537,
-0.030750418081879616,
0.019418982788920403,
-0.003743220353499055,
-0... |
for osteoporosis independent of BMD\nand is one of the strongest risk factorsfor subsequent fractures, especially in the\nfirst 1–2 years after a fracture (41,42). Os-\nteoporotic hip fractures are associated\nwith signifi cant morbidity, mortality, and\nsocietal costs (43). It is estimated that 20%of individuals do not ... | [
-0.03562562167644501,
-0.022999120876193047,
0.049253225326538086,
-0.0032847931142896414,
-0.006286963354796171,
-0.015986217185854912,
-0.04819072410464287,
0.09230132400989532,
-0.038687463849782944,
0.02389173023402691,
-0.04840462654829025,
0.043085742741823196,
0.012062867172062397,
... |
hip fracture, while 60% do not regain their\nprior functionality, living with permanentdisability (44).\nHip fractures in people with diabetes\nare associated with higher risk of mor-tality (28% in women and 57% in men),\nlonger recovery, and delayed healing\n(45) compared with individuals withoutdiabetes.\nEpidemiolog... | [
-0.027216291055083275,
0.006980587728321552,
0.007994008250534534,
0.048220060765743256,
-0.03173287585377693,
-0.018974412232637405,
0.012453227303922176,
0.052095863968133926,
-0.019879844039678574,
-0.0012819940457120538,
-0.032323889434337616,
0.08100125193595886,
-0.07652164250612259,
... |
Epidemiology and Risk Factors\nAge-speci fic fracture risk is signi ficantly\nincreased in people with type 1 or type 2diabetes in both sexes, with a 34% in-c r e a s ei nf r a c t u r er i s kc o m p a r e dw i t h\nthose without diabetes (46).\nType 1 Diabetes. Fracture risk in people | [
-0.003187847789376974,
-0.019528420642018318,
0.0031878931913524866,
0.04066145792603493,
-0.030440939590334892,
-0.012580816633999348,
0.046165306121110916,
0.09883363544940948,
-0.08891577273607254,
0.04903031885623932,
-0.008554674685001373,
0.02665211446583271,
-0.06731882691383362,
-0... |
those without diabetes (46).\nType 1 Diabetes. Fracture risk in people\nwith type 1 diabetes is increased by4.35 times for hip fractures, 1.83 times\nfor upper limb fractures, and 1.97 timesfor ankle fractures (47). Fractures occureven at young ages, 10 –15 years earlier | [
-0.011640634387731552,
0.03584140166640282,
0.01771373115479946,
0.059781309217214584,
-0.037460971623659134,
-0.009548168629407883,
0.0487077422440052,
0.06460267305374146,
-0.04920973256230354,
0.031488604843616486,
-0.03248720243573189,
0.09905218333005905,
-0.036038920283317566,
-0.037... |
than they do in people without diabetes,and are less frequent at the vertebrallevel. Type 1 diabetes is often associatedwith low bone mass, although BMDunderestimates the high risk of fracture\nobserved even in young individuals (47).\nType 2 Diabetes. In people with type 2\ndiabetes, hip fracture risk is increased | [
0.016596166417002678,
0.005118025001138449,
-0.007824577391147614,
0.05711783468723297,
-0.06057608127593994,
-0.07515740394592285,
0.007145855575799942,
0.06773290783166885,
-0.016398217529058456,
0.022037826478481293,
-0.053941357880830765,
0.10571607202291489,
-0.03748379275202751,
-0.0... |
diabetes, hip fracture risk is increased\nby 1.79 times, and risk throughout life\nis 40 –70% higher than in it is in individ-\nuals without diabetes (46,48). Fracturerisk is increased also in the upper limbsand ankle. Hip fracture risk is increased\neven at early stages of the disease de- | [
-0.023479001596570015,
0.039440590888261795,
-0.001346777193248272,
0.03281983360648155,
-0.028806913644075394,
-0.007010284345597029,
-0.0017933278577402234,
0.112752266228199,
-0.015050848014652729,
0.04195709899067879,
-0.04265894368290901,
0.08010876923799515,
0.003018510527908802,
-0.... |
even at early stages of the disease de-\ns p i t en o r m a lo rh i g h e rB M D( 4 9 , 5 0 ) .However, bone loss is accelerated, andlow BMD remains an independent riskfactor for fractures (51).\nGlucose control signi ficantly impacts | [
-0.04165581986308098,
-0.02918514981865883,
0.02987501583993435,
0.007281818427145481,
-0.011694978922605515,
0.021763652563095093,
-0.0869762971997261,
0.15088574588298798,
-0.00561169721186161,
0.08088014274835587,
0.004113386385142803,
0.06044837087392807,
0.022773824632167816,
-0.01202... |
Glucose control signi ficantly impacts\nfracture risk in people with diabetes. Ameta-analysis revealed an 8% increasedfracture risk per 1% rise in A1C level(risk ratio [RR] 1.08 [95% CI 1.03 –1.14])\n(52). Poor glycemic control (A1C >9%) | [
0.006205274723470211,
0.017299234867095947,
-0.0484522208571434,
0.08291182667016983,
-0.022488024085760117,
0.03826804459095001,
0.021452661603689194,
0.1175113171339035,
-0.014162665233016014,
0.03580677509307861,
-0.03534707799553871,
0.053819794207811356,
-0.04216388240456581,
-0.03594... |
(52). Poor glycemic control (A1C >9%)\nover 2 years in individuals with type 2diabetes correlated with a 29% height-ened fracture risk (53). Notably, this riskwas higher in the White demographicthan in other racial groups. Hypoglyce-\nmia also escalated the risk of fractures | [
0.059137456119060516,
0.02772424928843975,
-0.0072952876798808575,
0.1172386035323143,
-0.05758544057607651,
-0.002911146730184555,
-0.007994034327566624,
0.06486380845308304,
-0.08050572127103806,
0.006097827572375536,
-0.055453136563301086,
0.01126785296946764,
-0.06355734169483185,
-0.0... |
mia also escalated the risk of fractures\nat the hip and other skeletal sites (RR1.52 [95% CI 1.23 –1.88]) (52). A Japa-\nnese study echoed these findings, show-\ning a fracture risk increase (hazard ratio\n[HR] 2.24 [95% CI 1.56 –3.21]) with se-\nvere hypoglycemia episodes (54).\nLonger disease duration further ele- | [
-0.01800445467233658,
0.03944123536348343,
0.01960039883852005,
0.043236058205366135,
0.02943645976483822,
0.005329686217010021,
-0.06085337698459625,
0.1255212277173996,
-0.04041888192296028,
0.012603580951690674,
0.04033161699771881,
0.011149400845170021,
0.033004917204380035,
0.00180570... |
vere hypoglycemia episodes (54).\nLonger disease duration further ele-\nvates fracture risk (55); data indicate indi-\nviduals with T2D for >10 years and those\nwith type 1 diabetes for >26 years face\nsignifi cantly higher fracture risks, which | [
-0.008715138770639896,
0.009991249069571495,
0.06209516152739525,
0.03885595127940178,
-0.03130415081977844,
-0.02884804829955101,
-0.05129507929086685,
0.12521065771579742,
-0.06537342816591263,
0.02893923409283161,
-0.03705592453479767,
0.03578715771436691,
-0.053826987743377686,
-0.0105... |
signifi cantly higher fracture risks, which\nare largely attributed to ensuing micro-vascular and macrovascular damage af-fecting the skeleton. Additionally, highfracture risk is seen in people with car-\ndiovascular issues, nephropathy, retinop-\nathy, neuropathy, and frequent falls (45,56–59).\nCertain glucose-lowerin... | [
-0.0035859551280736923,
0.01805318333208561,
0.0363568551838398,
0.022863442078232765,
-0.06767576187849045,
-0.009713592939078808,
-0.06597297638654709,
0.1935288906097412,
-0.049595002084970474,
0.028912043198943138,
-0.022001171484589577,
0.08004806935787201,
-0.03117494471371174,
0.037... |
Certain glucose-lowering medications\nalso factor into fracture risk. Studies have\nreported increased fracture incidences in\nwomen using thiazolidinediones (TZD),with the risk doubling with 1 –2 years of\nTZD use (HR 2.23 [95% CI 1.65 –3.01])\n(60,61). According to the Action to Control\nCardiovascular Risk in Diabet... | [
-0.029597317799925804,
0.03342730179429054,
-0.024800539016723633,
0.03755572438240051,
-0.06250620633363724,
-0.016213659197092056,
-0.00821740087121725,
0.1675793081521988,
-0.03342030569911003,
0.06959939748048782,
-0.03086828999221325,
0.08668079227209091,
-0.06070940941572189,
0.03154... |
Cardiovascular Risk in Diabetes (ACCORD)\nstudy, reduced risk is noted in women whohad discontinued TZD use for 1 –2 years\n(HR 0.57 [95% CI 0.35 –0.92]) or >2 years\n(HR 0.42 [95% CI 0.24 –0.74]) compared | [
0.032122474163770676,
0.09552872180938721,
-0.061586953699588776,
0.07690481841564178,
-0.01852429285645485,
0.023740800097584724,
-0.012495454400777817,
0.08787167817354202,
0.0038874607998877764,
-0.013874609023332596,
-0.01713383197784424,
0.047764770686626434,
-0.055676642805337906,
-0... |
(HR 0.42 [95% CI 0.24 –0.74]) compared\nwith current users (62). Furthermore, indi-viduals with type 2 diabetes on insulin (RR1.49 [95% CI 1.29– 1.73]) or sulfonylurea(RR 1.30 [95% CI 1.18 –1.43]) treatment ex-\nhibit a heightened fracture risk (63).\nScreening | [
-0.030598362907767296,
-0.03822266682982445,
-0.04812321811914444,
0.033942028880119324,
-0.04818401858210564,
-0.028946036472916603,
0.0029179283883422613,
0.1594758927822113,
-0.07023259997367859,
-0.04853824898600578,
-0.04926983639597893,
0.026598414406180382,
-0.05169714614748955,
0.0... |
hibit a heightened fracture risk (63).\nScreening\nMost evidence on screening in individu-als at risk for fracture is available frompeople with type 2 diabetes, while frac-\nture risk prediction in type 1 diabetes | [
-0.007829083129763603,
-0.012335785664618015,
0.005621126852929592,
0.04220541939139366,
0.004488276783376932,
-0.01165417954325676,
-0.00519156688824296,
0.09111703187227249,
-0.07845120131969452,
0.005063218995928764,
-0.052122630178928375,
0.04182605817914009,
-0.062268584966659546,
-0.... |
ture risk prediction in type 1 diabetes\nhas not been explored. Health care pro-fessionals should assess fracture historyand risk factors in older people with di-abetes and recommend measurement\nof BMD if appropriate according to the\nindividual ’s age and sex.\nType 2 Diabetes. People with type 2 diabe-\ntes have 5 –... | [
-0.030831700190901756,
-0.07409269362688065,
0.005225869361311197,
0.051588404923677444,
-0.029323697090148926,
0.0009149560355581343,
0.038391124457120895,
0.06891604512929916,
-0.14061713218688965,
-0.006123079918324947,
-0.06911792606115341,
0.009309744462370872,
-0.05856294929981232,
-... |
tes have 5 –10% higher BMD than people\nwithout diabetes. A T-score adjustment of/C00.5 has been proposed to improve frac-\nture prediction by dual-energy X-ray ab-sorptiometry (DXA). For example, a T-score#/C02.0 should be interpreted as equiva-\nlent to /C02.5 in a person without diabetes | [
-0.03492307662963867,
-0.007567800115793943,
-0.035676196217536926,
0.0677090734243393,
0.0008788527920842171,
0.015270544216036797,
0.004870356526225805,
0.17231455445289612,
-0.012690214440226555,
0.014905545860528946,
-0.040588535368442535,
-0.05426269397139549,
-0.04072921723127365,
0.... |
lent to /C02.5 in a person without diabetes\n(51). Notably, the Fracture Risk AssessmentTool (FRAX), although useful, does not fac-tor in type 2 diabetes; an inclusion of thecondition is estimated to mirror the effect\nof either a 10-year age increase or a | [
-0.0050140866078436375,
0.004025242291390896,
-0.00839213002473116,
0.04264833778142929,
-0.0011250772513449192,
0.002519292989745736,
0.0008810524013824761,
0.1148855909705162,
-0.015040474012494087,
-0.01241911482065916,
-0.0335574708878994,
-0.00008972812065621838,
-0.04002135619521141,
... |
of either a 10-year age increase or a\n0.5 SD reduction in BMD T-score (64).Fracture risk was higher in large obser-vational studies in participants with dia-betes compared with those without\ndiabetes for a given T-score and age or | [
-0.007232041098177433,
0.02300103008747101,
0.046444471925497055,
0.024682117626070976,
-0.034175485372543335,
0.05069977417588234,
-0.02263159677386284,
0.14456774294376373,
-0.03629912808537483,
0.05244588851928711,
-0.015414426103234291,
0.03366927430033684,
-0.04538644850254059,
0.0203... |
diabetes for a given T-score and age or\nfor a given FRAX score (51). Additionally,integrating the diagnosis of rheumatoidarthritis in FRAX can potentially improvefracture risk prediction for people with\ntype 2 diabetes. Growing evidence sug- | [
0.011064800433814526,
-0.018338672816753387,
-0.0005166688351891935,
0.06694906949996948,
0.04886651039123535,
0.03843841701745987,
-0.04229583591222763,
0.15797457098960876,
-0.03103877231478691,
0.007292668800801039,
-0.11808616667985916,
0.08336002379655838,
0.03323328495025635,
0.02604... |
type 2 diabetes. Growing evidence sug-\ngests that fracture risk prediction is en-hanced by use of trabecular bone score(64), although such studies are not availablefor individuals with type 1 diabetes and are\nbased on data from the U.S. or Canada.\nIn people with type 2 diabetes, in the\nabsence of other comorbiditie... | [
-0.007874906063079834,
-0.05208567529916763,
0.023866118863224983,
0.07092846184968948,
-0.037450551986694336,
-0.033456139266490936,
0.022042306140065193,
0.08701328933238983,
-0.05702716112136841,
0.06461290270090103,
-0.04034388065338135,
0.0698077455163002,
-0.06869220733642578,
0.0049... |
absence of other comorbidities, DXA scan\nshould be performed at least 5 years afterthe diagnosis of diabetes, and reassess-ment is recommended every 2 –3 years\n(64) depending on the screening evalua-tion and the presence of additional riskfactors ( Table 4.5 ). According to the Euro- | [
-0.00022226863075047731,
-0.008217349648475647,
-0.04361335188150406,
0.024213964119553566,
-0.05095076188445091,
-0.033656295388936996,
-0.016940172761678696,
0.04138299450278282,
-0.05966464802622795,
-0.0497177392244339,
0.013116828165948391,
0.08457116782665253,
-0.059750642627477646,
... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.